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Abstract
Background: Type 1 diabetes mellitus (T1D) is characterized by autoimmune responses resulting in destruction of
insulin-producing pancreatic beta cells. Multipotent mesenchymal stromal cells (MSCs) exhibit immunomodulatory
potential, migratory capacity to injured areas and may contribute to tissue regeneration by the secretion of bioactive
factors. Therefore, MSCs are considered as a promising approach to treat patients with different autoimmune diseases
(AID), including T1D patients. Phenotypical and functional alterations have been reported in MSCs derived from
patients with different AID. However, little is known about the properties of MSCs derived from patients with T1D.
Since autoimmunity and the diabetic microenvironment may affect the biology of MSCs, it becomes important to
investigate whether these cells are suitable for autologous transplantation. Thus, the aim of the present study was to
evaluate the in vitro properties and the in vivo therapeutic efficacy of MSCs isolated from bone marrow of newly
diagnosed T1D patients (T1D-MSCs) and to compare them with MSCs from healthy individuals (C-MSCs).
Methods: T1D-MSCs and C-MSCs were isolated and cultured until third passage. Then, morphology, cell diameter,
expression of surface markers, differentiation potential, global microarray analyses and immunosuppressive
capacity were in vitro analyzed. T1D-MSCs and C-MSCs therapeutic potential were evaluated using a murine
experimental model of streptozotocin (STZ)-induced diabetes.
Results: T1D-MSCs and C-MSCs presented similar morphology, immunophenotype, differentiation potential, gene
expression of immunomodulatory molecules and in vitro immunosuppressive capacity. When administered into
diabetic mice, both T1D-MSCs and C-MSCs were able to reverse hyperglycemia, improve beta cell function and
modulate pancreatic cytokine levels.
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Conclusions: Thus, bone marrow MSCs isolated from T1D patients recently after diagnosis are not phenotypically
or functionally impaired by harmful inflammatory and metabolic diabetic conditions. Our results provide support
for the use of autologous MSCs for treatment of newly diagnosed T1D patients.
Keywords: Mesenchymal stromal cells, Type 1 diabetes mellitus, Immunomodulation, Cell transplantation,
Streptozotocin-induced diabetes
Background
Type 1 diabetes mellitus (T1D) is a chronic disease char-
acterized by an autoimmune response in which cellular
immunity plays a pivotal role in the selective destruction
of insulin-producing pancreatic beta (β) cells, thus lead-
ing to metabolic dysfunction. While insulin replacement
stands as the main therapeutic approach for T1D pa-
tients, it is insufficient to prevent long-term complica-
tions such as vascular dysfunction, retinopathy, and
kidney failure [1]. Possible alternative treatments, such
as human pancreas and islet transplantation, are limited
by lack of sufficient donors, high costs, and need for
chronic post-transplant immunosuppression [2]. In
addition, the immune regulation and preservation of
the β-cell mass have been attempted by the administra-
tion of immunosuppressive agents such as prednisone,
azathioprine, and cyclosporine in several clinical trials.
However, adverse effects of such drugs and the need for
continuous treatment have limited the application of
these therapies [3]. These difficulties have prompted re-
search into the development of alternative and innova-
tive methods to treat T1D patients.
In this sense, adult stem cell transplantation represents a
promising possibility that must be explored. High-dose im-
munosuppression followed by autologous hematopoietic
stem cell transplantation was shown to increase C-peptide
levels with reduction or even suspension of insulin use in
the majority of newly diagnosed T1D patients [4]. In
addition, multipotent mesenchymal stromal cells (MSCs)
have also attracted great attention as a powerful tool for
T1D treatment because of their regenerative and immuno-
modulatory properties.
MSCs are multipotent mesenchymal precursors found
in several tissues. Considering the possible perivascular
origin of MSCs, it has been suggested that MSCs may be
present in any vascularized tissue throughout the whole
body [5]. MSCs express different nonspecific surface
molecules (including CD90, CD73, CD105, CD29, CD44,
and CD166), but do not express endothelial or
hematopoietic markers (CD31, CD45, CD43, CD14,
CD11b), major histocompatibility complex (MHC) class
II molecule, and costimulatory proteins (CD80, CD86,
CD40) [6, 7]. The first described MSC function was to
provide cytokines and growth factors to support the
hematopoietic process. Moreover, these cells have the
capacity to differentiate in vitro into cell types from con-
nective tissue such as adipocytes, chondroblasts, and os-
teoblasts [8]. In addition, MSCs migrate to injured
tissues and may promote regeneration by the secretion
of several bioactive factors [9].
MSCs have been shown to have immumodulatory and
immunosuppressive properties, both in vitro and in vivo
[10]. MSCs modulate the function of T and B lymphocytes
[11, 12], dendritic cells [13], natural killer cells [14], and
regulatory T (Treg) cells [15]. Cell-to-cell contact and the
production of immumodulatory soluble factors such as
transforming growth factor beta (TGF-β), indoleamine
2,3-dioxygenase (IDO), prostaglandin E2, interleukin (IL)-
10, and hepatic growth factor (HGF) are involved in these
processes [16]. On the other hand, MSCs have their regu-
latory functions activated (“licensed”) by inflammatory
cytokines such as tumor necrosis factor alpha (TNFα),
interferon gamma (IFNγ), and IL-1β, as well as by Toll-
like receptor (TLR) signaling [17].
In the last decades, MSCs have been the focus of cell-
based therapy research, especially for treatment of in-
flammatory and autoimmune diseases (AID) [18].
MSCs have been extensively used to treat chemically-
induced and spontaneous experimental T1D models.
Administration of MSCs in diabetic mice/rats delayed
the onset of disease, significantly decreased blood glu-
cose levels, increased endogenous insulin production,
modulated the expression of cytokines, reduced the
pancreatic inflammatory process, and induced the ex-
pansion of Treg cells [19–21]. These promising results
have stimulated ongoing worldwide clinical trials to test
safety and therapeutic potential of MSCs in T1D patients
[22]. Noteworthy, most of these trials use allogeneic MSCs
from healthy individuals instead of autologous cells. Gen-
erally, autologous rather than allogeneic cells are preferred
in the transplantation setting, avoiding the risks of im-
mune rejection or transfer of donor-derived infections
and other diseases [23]. In this perspective, a fundamental
question that must be addressed is whether MSCs from
patients with AID preserve their functional properties or
may be somehow compromised [24, 25].
Phenotypical and functional characteristics of MSCs
derived from patients with different AID have been in-
vestigated in the past years [26]. MSCs from systemic
sclerosis (SS) patients and from healthy donors exhibited
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similar proliferation rates, differentiation potential, and in
vitro T-lymphocyte inhibition capacity [27]. Conversely,
MSCs isolated from patients with rheumatoid arthritis
(RA) [28], multiple sclerosis (MS) [29], and immune trom-
bocytopenic purpura (ITP) [30] showed defects in critical
cell functions. These alterations might be due to disease-
related cellular, molecular, and/or biochemical changes in
the bone marrow microenvironment.
In T1D setting, the autoimmune process and metabolic
alterations could affect MSCs properties. To date, to our
knowledge there are no existing data regarding biological
and immunological profiles of MSCs isolated from newly
diagnosed T1D patients. Whether these cells are pheno-
typically and/or functionally abnormal is thus an import-
ant question to be addressed in the context of autologous
transplantation. The purpose of the present study is there-
fore to evaluate the in vitro properties and the in vivo
therapeutic efficacy of MSCs isolated from newly diag-
nosed T1D patients in experimental diabetes.
Methods
Subjects
Bone marrow samples were obtained from the iliac crest
of newly diagnosed T1D patients and healthy donors, after
informed consent. Patients (all males; 23.2 ± 2.9 years;
273.83 ± 31.09 mg/dl fasting blood glucose; 9.5 ± 0.7 %
HbA1c levels; 19.3 ± 2.0 mean body mass index) enrolled
in this study were diagnosed with T1D in the previous
6 weeks, confirmed by positive serum levels of anti-
glutamic acid decarboxylase (anti-GAD) antibodies (22.66
± 15.04 U/ml) and without previous episodes of diabetic
ketoacidosis. All patients presented symptoms of hypergly-
cemia (polyuria, polydipsia, and weight loss) at diagnosis.
Healthy subjects (all males; 33.1 ± 4.9 years; fasting blood
glucose <100 mg/dl) were recruited among voluntary bone
marrow donors. All human procedures were approved by
the Ethics Committee of the University Hospital (Ribeirão
Preto Medical School, Ribeirão Preto, Brazil), at the Univer-
sity of São Paulo, Ribeirão Preto, Brazil (# 10095/02).
MSC isolation, culture, and characterization
Bone marrow aspirate samples were collected in pres-
ence of ethylenediamine tetraacetic acid (EDTA), and
mononuclear cells were separated using Ficoll-Hypaque
(Amersham-Pharmacia, Uppsala, Sweden) gradient dens-
ity. Subsequently, the mononuclear cell layer was har-
vested, washed, centrifuged, and resuspended in alpha
minimum essential medium (αMEM; Gibco Life Tech-
nologies, Grand Island, NY, USA) supplemented with
15 % fetal bovine serum (FBS; Thermo Scientific, Rock-
ford, IL, USA), 100 μg/ml penicillin (Gibco), 100 μg/ml
streptomycin (Gibco), and 2 mML‐glutamine (Gibco).
The cells were then seeded in 75 cm2 flasks and incu-
bated at 37 °C with 5 % CO2. After 7 days, nonadherent
cells were removed and fresh medium was added twice a
week. When layers were confluent, the cells were de-
tached using trypsin (Gibco) and subcultured until third
passage. The methods used for analysis of morphology,
immunophenotypic profile, and adipocyte differentiation
potential of bone marrow-isolated MSCs are described
in Additional file 1.
Microarray analysis
Total RNA was isolated from MSCs from bone marrow
of healthy individuals (C-MSCs; n = 4) and MSCs from
bone marrow of newly diagnosed T1D patients (T1D-
MSCs; n = 4) using Trizol (Invitrogen LifeTechnologies,
Carlsbad, CA, USA), according to the manufacturer’s in-
structions, purified with the RNeasy mini Kit (Qiagen,
Valencia, CA, USA), and analyzed by spectrophotometry
at 260 and 280 nm (NanoDrop, ND‐1000 UV‐VIS;
Thermo Fisher Scientific, Walthman, MA, USA). Global
gene expression analyses were performed by the One-
color Microarray-Based Gene Expression Analysis Proto-
col system (Agilent Technologies, Santa Clara, CA,
USA) on glass slides with four microarrays of 44,000
probes each (4 × 44 k; Agilent Technologies). The pre-
process and statistical microarray analyses were per-
formed using algorithms available from the R platform
the Linear Models for Microarray Data (LIMMA, R Foun-
dation, Vienna, Austria) package. The heatmaps were gen-
erated by the HeatMapViewer module from GenePattern
2.0 software (Broad Institute, Cambridge, MA, USA).
Genes exhibiting P <0.05 and differences in expression of
at least 2.0-fold (up or down) were considered statisti-
cally significant. Microarray data were deposited in the
public database ArrayExpress (http://www.ebi.ac.uk/
arrayexpress), access code E-MTAB-2976.
Lymphocyte proliferation assay
To test the inhibitory effects of T1D-MSCs and C-MSCs
on allogeneic lymphocyte proliferation, the carboxyfluo-
rescein diacetate succinimidyl ester (CFSE; Invitrogen
LifeTechnologies) dilution method was used. Peripheral
blood mononuclear cells (PBMCs) obtained from healthy
donors were separated by Ficoll-Hypaque density gradi-
ent (Amersham-Pharmacia), labeled with CFSE (10 μM,
for 10 minutes at 37 °C), and resuspended in RPMI 1640
medium (Gibco) supplemented with 5 % human serum
albumin (Vialebex® 200 mg/ml; LFB, Rio de Janeiro,
Brazil). CFSE-labeled PBMCs were added to the wells
containing previously adhered patient or control MSCs,
in six different ratios (MSCs:PBMCs = 1:2, 1:5, 1:10, 1:20,
1:50, and 1:100) in the presence of 0.5 μg/ml phytohem-
agglutinin (PHA; Sigma‐Aldrich, St. Louis, MO, USA).
The cocultures were incubated for 5 days at 37 °C with
5 % CO2. Subsequently, PBMCs were harvested, stained
with anti‐CD3 antibody (BD, San Jose, CA, USA) and
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the dilution of CFSE in CD3+ T cells was analyzed by
flow cytometry using FACSCalibur™ (BD) equipment.
In vivo analysis: experimental design
In vivo experiments were designed according to the
protocol represented in Additional file 2: Figure S1.
Induction of experimental diabetes
C57BL/6 male mice 10 weeks of age were intraperitoneally
injected with 40 mg/kg streptozotocin (STZ; Sigma-
Aldrich) for 5 consecutive days. STZ was diluted in so-
dium citrate buffer, pH 4.5. Blood samples were taken
from the tail vein of nonfasting mice, and glucose levels
determined with a glucometer system Accu-Chek Active
(Roche Diagnostics, Abbott Park, IL, USA). Mice were
considered diabetic when glycemia exceeded 250 mg/dl in
two consecutive determinations. All animal procedures
were approved by the Ethics Committee for Animal Re-
search of the Ribeirão Preto Medical School (# 157/2010;
# 021/2013-01).
Intrasplenic transplantation of MSCs
Single doses of 1 × 106 T1D-MSCs or C-MSCs were
injected into the spleens of diabetic mice (n = 9/group)
20 days after the last dose of STZ. The control group re-
ceived intrasplenic injections of phosphate-buffered saline
(PBS; n = 6).
For intrasplenic injections of MSCs or PBS, mice were
anaesthetized with a mixture of ketamine (Ketamina-
Agener União, São Paulo, Brazil) and xylazine (Dopaser-
Hertape Calier, Minas Gerais, Brazil). The spleens were
exposed after skin and peritoneum incisions and re-
ceived single MSCs or PBS microinjection (70 μl of final
volume). Bleeding was controlled using cotton swabs
and local application of fibrin sealant. Incisions were
sutured with a 5–0 nylon monofilament (Bioline Fios
Cirúrgicos Ltda, Goiás, Brazil). Intraperitoneal injections
of tramadol hydrochloride (30 mg/kg, Tramal; Medley,
Campinas, Brazil) were used as pain relief every 12 hours
for 3 consecutive days.
Nonfasting glucose was monitored every 5 days using
the glucometer system Accu-Chek Active (Roche Diag-
nostics). Mice were sacrificed 35 days after MSC or PBS
injection and the pancreas, spleen, pancreatic lymph
nodes, and blood samples were collected (Additional file
2: Figure S1).
Glucose tolerance test
Peripheral response to glucose was evaluated by intra-
peritoneal glucose tolerance test (GTT) 30 days after C-
MSC or T1D-MSC transplantation. Glucose solution
(1.5 mg/g body weight) was intraperitoneally adminis-
trated in 10-hour fasting mice, and blood glucose levels
were determined before and 15, 30, 60, and 180 minutes
after glucose administration.
Histology and immunohistochemistry analysis
For histologic analysis, pancreata were removed, fixated
in 10 % neutral buffered formalin, and embedded in
paraffin and the sections (5 μm) were stained with
hematoxylin and eosin (H & E). Immunohistochemistry
reactions were performed on formalin-fixed or frozen
Tissue-Tek O.C.T (Sakura Finetek, Zoeterwoude, the
Netherlands) tissue sections. First, sections were incu-
bated with Peroxidase-Blocking Reagent (DAKO Cyto-
mation, Fort Collins, CO, USA) to block endogenous
peroxidase. The slides were then incubated with a block-
ing solution containing PBS/bovine albumin serum 1 %
(Sigma)/Triton X-100 (BioRad, Richmond, CA, USA) to
prevent unspecific staining. Next, rabbit monoclonal
anti-mouse insulin antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) or rabbit anti-mouse Ki-67 anti-
body (Abcam, Cambridge, UK) were applied to the sec-
tions, followed by incubation with LSAB™ + Kit/HRP
(DAKO Cytomation). The slides were stained with di-
aminobenzidine according to the manufacturer’s instruc-
tions (DAKO Cytomation). Finally, the sections were
counterstained with Harris hematoxylin and analyzed
under light microscopy.
Isolation of cells from spleens and pancreatic lymph nodes
Each spleen was mashed and the resulting cell suspension
collected. Next, erythrocytes were lysed using Tris 0.17 M
+NH4Cl 0.16 M buffer. Tubes containing the splenocytes
received RPMI 1640 medium (Gibco) supplemented with
10 % FBS, 2 mmol/l L-glutamine (Gibco), and 100 U/ml
penicillin/streptomycin (Gibco) and were centrifuged at
300 × g for 10 minutes at 4 °C. The supernatants were
then discarded and pellets resuspended in RPMI 1640
medium (Gibco). Pancreatic draining lymph nodes (PLN)
were collected and mashed through a cell strainer into a
Petri dish containing RPMI 1640 medium (Gibco). The
cell suspension was then collected and centrifuged at
300 × g for 10 minutes at 4 °C.
Flow cytometry analysis of CD4+CD25+Foxp3+ Treg cell
population
First, the cell suspension (splenocytes or PLNs) was
incubated with 100 μl rabbit normal serum 5 % for
30 minutes to block nonspecific binding. Next,
fluorochrome-conjugated primary antibodies against
CD4 and CD25 antigens and their control isotypes
(BD) were added and incubated for 30 minutes at
room temperature in the dark. All monoclonal anti-
bodies were used at concentrations recommended by the
manufacturer (BD). After extracellular antigen staining,
cells were incubated with FACS Lysing solution (BD) for
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10 minutes in the dark. They were then washed and resus-
pended in FACS permeabilizing solution (BD) for 10 mi-
nutes. Next, the expression of the transcription factor
Foxp3 was assessed by incubating with PE-conjugated
anti-mouse Foxp3 monoclonal antibody (BD). Cell sus-
pension was washed, resuspended, and analyzed using a
FACSCalibur™ flow cytometer (BD). Data were obtained
for 100,000 events/sample (spleen) or 50,000 events/sam-
ple (PLN) using CellQuest Pro software (BD).
Quantification of cytokine levels in serum and in
pancreatic tissue
Pieces of pancreas were removed, weighed, and placed in
a tube containing 700 μl Complete Protease Inhibitor
Cocktail (Roche Diagnostics). Pancreatic tissue was ho-
mogenized using a Polytron homogenizer (Kinematica,
Luzern, Switzerland) and IL-2, IL-6, IFNγ, TNFα, IL-17,
IL-4, and IL-10 levels were detected by the cytometric
bead array (CBA) (Th1/Th2/Th17 kit; BD) method, ac-
cording to the manufacturer’s instructions. The concen-
tration of TGF-β in pancreatic tissue was determined
using Human/Mouse TGF-β1 ELISA Ready-Set-Go kit
(eBioscience, San Diego, CA, USA). Serum cytokine levels
were also determined by the CBA method.
Quantification of serum insulin
Blood samples of nonfasting mice were collected 35 days
after MSC/PBS administration. The serum insulin con-
centration was determined using the Mouse Ultrasensi-
tive Insulin ELISA kit (Alpco Diagnostics, Salem, MA,
USA), according to the manufacturer’s instructions.
Statistical analysis
Data are presented as mean ± standard deviation (SD).
Statistical comparisons included unpaired/paired t tests or
one-way analysis of variance with Tukey’s post test. P <0.05
was considered significant.
Results
T1D-MSCs exhibit morphology, immunophenotypic
profile, and adipocyte differentiation capacity similar to
MSCs from healthy counterparts
To characterize T1D-MSCs, we evaluated the cell morph-
ology, cell diameter, expression of surface markers, and in
vitro differentiation potential, and compared results with
those from their healthy counterparts.
MSCs isolated from bone marrows of healthy donors
(C-MSCs) and newly diagnosed T1D patients (T1D-
MSCs) appeared as typical monolayers of spindle-shaped
fibroblast-like cells, with ability to adhere to plastic dur-
ing in vitro expansion. At the third passage, T1D-MSCs
in culture were morphologically similar to C-MSCs
(Fig. 1a). The mean cell size (diameter) of T1D-MSCs in
suspension (15.32 ± 0.56 μm) was also similar to that of
C-MSCs (15.35 ± 0.71 μm; Fig. 1b).
T1D-MSC and C-MSC samples presented typical MSC
phenotype and similar percentages of CD73, CD90,
CD105, CD29, CD13, CD44, CD49e, CD54, HLA-I,
CD166, CD106, STRO-1, CD45, CD14, CD34, HLA-II,
CD51/61, and KDR positive cells (Fig. 1c).
To evaluate the in vitro adipogenic differentiation po-
tential, T1D-MSCs and C-MSCs were cultured for
21 days with specific medium to induce differentiation
into adipocytes. T1D-MSCs and C-MSCs were both
able to differentiate towards the adipogenic lineage, and
cytoplasmic lipid vesicles were detected by Sudan II-
Scarlet staining (Fig. 1d). Adipocyte size was deter-
mined using morphometric analysis and no differences
were observed comparing both MSC sources (C-MSCs
1.19 ± 0.54 × 103 μm2 versus T1D-MSCs 1.07 ± 0.62 ×
103 μm2, P >0.05; data not shown).
Gene expression of immunomodulatory molecules in
T1D-MSCs is similar to C-MSCs
To evaluate the differential expression of genes that code
immunomodulatory molecules and factors involved in
MSC licensing, we performed global microarray analyses
of T1D-MSCs and C-MSCs. No significant differences
(P >0.05, fold-change ≥2) were observed in the expres-
sion of PDL1, NOS2, IL10, PTGES, TGFB1, PDL2, HLAG,
and TGS6 genes in T1D-MSCs compared with C-MSCs.
However, the HGF gene was significantly downregulated
in T1D-MSCs. The expression of licensing-related genes
(IFNGR1, IFNGR2, TNFR1, TNFR2, TLR3, TLR4) was also
similar in T1D-MSCs compared with C-MSCs (Fig. 2).
T1D-MSCs exhibit preserved in vitro immunosuppressive
potential
Once T1D-MSCs showed no significant alterations in
the expression of immunomodulatory genes, we com-
paratively assessed their immunosuppressive capacity in
cocultures with activated PBMCs. T1D-MSCs and C-
MSCs were able to efficiently suppress the proliferation
of CD3+ cells in a dose‐dependent manner, in the ratios
(MSCs/PBMCs) of 1/2, 1/5, 1/10, and 1/20. Comparing
the suppressive capacity of T1D-MSCs with C-MSCs,
no significant differences were observed in all evaluated
concentrations (Fig. 3a, b).
Administration of T1D-MSCs promotes glycemic control
and improves peripheral response to glucose in STZ-
induced diabetic mice
Since our in vitro analyses demonstrated that T1D-MSCs
presented morphological, transcriptional, and in vitro
functional characteristics similar to C-MSCs, we tested
their therapeutic potential using a murine experimental
model of STZ-induced diabetes. Single doses of 1 × 106
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Fig. 1 (See legend on next page.)
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cells (T1D-MSCs or C-MSCs) were directly injected
into the spleen of diabetic mice, while mice from the
diabetic control group received intrasplenic injection of
PBS (Control-PBS).
The administration of T1D-MSCs or C-MSCs equally
reversed hyperglycemia in 67 % (6/9) of mice (responder
mice). Blood glucose levels of T1D-MSC-treated or C-
MSC-treated responder mice were significantly lower
compared with those from the control group during
follow-up (Fig. 4a). The area under the glycemia curve
(AUC) of the C-MSC-treated responder group (7183.11 ±
839.11) was similar to the AUC of the T1D-MSC-treated
responder group (6568.33 ± 604.96). On the other hand,
AUCs were significantly lower in the cell-treated groups
than in the control group (11,728.17 ± 2805.10, P = 0.0002;
Fig. 4b). The fasting glycemia of the C-MSC-treated
(141.8 ± 9.08 mg/dl) and the T1D-MSC-treated (147.1 ±
17.53 mg/dl) responder groups were lower than that from
the control group (283.8 ± 29.50 mg/dl, P < 0.0001; data
not shown). Noteworthy, 100 % of T1D-MSC-treated and
C-MSC-treated mice exhibited fasting glucose levels lower
than 250 mg/dl.
Thirty days after treatment with T1D-MSCs or C-
MSCs, responder animals had improved response to
exogenous glucose compared with the control group
(Fig. 4c). Significant differences were observed when
(See figure on previous page.)
Fig. 1 Characterization of T1D-MSCs isolated. a Morphological characterization. At the third passage, C-MSCs (upper panel) and T1D-MSCs (lower panel)
showed homogeneous spindle-shaped fibroblast-like growth (Leishman staining, 100× and 400× magnification, respectively). b The diameter
of C-MSCs (n = 5) and T1D-MSCs (n = 5) in suspension was determined by ViCell XR equipment (2000 cells/sample). c Expression of surface
immunophenotypic markers. Graphs display the phenotype of MSCs in culture at the third passage. MSCs from T1D patients were phenotypic-
ally similar to those from healthy donors. Bars represent mean ± SD. d In vitro adipocyte differentiation. C-MSCs (upper panel) and T1D-MSCs
(lower panel) were able to differentiate towards adipogenic lineage. The presence of lipid vacuoles in the cytoplasm was identified by Sudan
II-Scarlet staining (100×, 200×, and 400× magnification, respectively). C-MSCs mesenchymal stromal cells from bone marrow of healthy individ-
uals, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients
Fig. 2 Heatmap of relative differential gene expression of immunosuppressive and licensing-related molecules in C-MSCs and T1D-MSCs. Global
gene expression analysis was performed in third-passage C-MSCs (n = 4, left panel) and T1D-MSCs (n = 4, right panel). Downregulated genes are
shown in green. Upregulated genes are presented in red. Differentially expressed genes are shown in bold (P <0.05, fold-change >2). Microarray
data were deposited in the public database ArrayExpress (http://www.ebi.ac.uk/arrayexpress), access code E-MTAB-2976. C-MSCs mesenchymal
stromal cells from bone marrow of healthy individuals, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients
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comparing the GTT AUC of T1D-MSC-treated (51,740.33
± 5005.53) and C-MSC-treated (45,880.17 ± 8219.11) re-
sponder mice with that from the control group (78,152.67
± 6979.88, P <0.0001; Fig. 4d).
T1D-MSC treatment decreases pancreatic inflammation
and improves pancreatic β-cell function
Pancreatic islets of PBS-treated diabetic mice presented
an inflammatory process (insulitis) 35 days after adminis-
tration of saline (Additional file 3: Figure S2). On the other
hand, C-MSC-treated and T1D-MSC-treated responder
mice did not exhibit islet infiltration in the same period.
Moreover, pancreatic islets from MSC-treated responder
mice were larger in size than those observed in the control
group (Fig. 5a).
We also investigated whether MSC therapy could pre-
serve or regenerate β cells by evaluating in situ insulin
expression in pancreatic islets. Pancreatic islets of T1D-
MSC-treated mice showed higher in situ insulin expres-
sion compared with the control group, and similar to the
C-MSC-treated group (Fig. 5a). The presence of Ki-67-
positive cells, reflecting pancreatic cells under prolifera-
tion, was similar in all experimental groups (Additional
file 4: Figure S3).
The concentration of serum insulin was higher in T1D-
MSC-treated responder mice (0.82 ± 0.09 ng/ml, P <0.007)
and C-MSC-treated responder mice (0.81 ± 0.12 ng/ml,
Fig. 3 T1D-MSCs efficiently inhibit in vitro T-cell proliferation. In coculture assays, different concentrations of phytohemagglutinin (PHA)-stimulated
allogeneic peripheral blood mononuclear cells (PBMCs) labeled with CFSE were cultured in the presence of C-MSCs (n = 6) or T1D-MSCs (n = 3).
The percentage of CD3+ T-lymphocyte proliferation was determined by flow cytometry. a Percentages of lymphocyte proliferation. b Percentages
of lymphocyte proliferation inhibition. Data expressed as mean ± SD. C-MSCs mesenchymal stromal cells from bone marrow of healthy individuals,
MSC multipotent mesenchymal stromal cell, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients
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P <0.02) compared with the control group levels (0.39
± 0.05 ng/ml) 35 days after MSCs or PBS administra-
tion (Fig. 5b).
T1D-MSC treatment does not affect the frequency of CD4
+CD25+Foxp3+ Treg cells in the spleen and lymph nodes
To evaluate whether T1D-MSC or C-MSC treatment
was associated with the induction/expansion of Treg
cells, we analyzed the frequency of CD4+CD25+Foxp3+
T cells in the spleen and PLN 35 days after PBS/MSC
administration. Frequencies of CD4+CD25+Foxp3+ T cells
in the spleen and PLN were similar in T1D-MSCs (2.27 ±
0.18 % and 0.51 ± 0.21 %), C-MSCs (2.28 ± 0.30 % and
0.43 ± 0.24 %), and control (2.07 ± 0.19 % and 0.51 ±
0.21 %) groups, respectively (Fig. 6).
T1D-MSC treatment modulates cytokine levels in the
pancreatic microenvironment
The levels of proinflammatory (IL-2, IL-6, IFNγ, TNFα,
IL-17) and anti-inflammatory (IL-4, IL-10) cytokines
were determined in the serum and pancreatic tissue
homogenate. No significant differences were observed in
serum cytokine levels of the different experimental
groups (Additional file 5: Figure S4). Significant reduc-
tion of IL-2 and IFNγ levels was observed in the pancreas
of MSC-treated responder mice (T1D-MSCs group: 90.20
± 55.86 pg/g and 3.92 ± 3.60 pg/g; C-MSCs group: 96.72 ±
46.36 pg/g and 6.09 ± 5.25 pg/g; control group: 161.96 ±
47.22 pg/g and 18.60 ± 8.22 pg/g; P <0.05). The levels of
pancreatic IL-4 were diminished in the T1D-MSC-treated
group (24.24 ± 8.58 pg/g) compared with the control
group (53.61 ± 24.05 pg/g, P = 0.02). Levels of IL-6, TNFα,
Fig. 4 Intrasplenic injection of T1D-MSCs promotes reversion of hyperglycemia and improvement of peripheral response to glucose in STZ-induced
diabetic mice. T1D-MSCs or C-MSCs (1 × 106) were administered by intrasplenic injection in diabetic mice 20 days after diabetes induction. a Blood
glucose levels (mg/dl) were frequently measured in nonfasting mice for 35 days. A reduction in blood glucose levels was observed in 67 % (6/9) of
diabetic MSC-treated mice mainly on day 6 post transplantation (only the glycemic levels of responder mice/n = 6 are shown). The control group was
treated with intrasplenic injection of PBS (Control-PBS, n = 6). b Area under the curve of glycemia (AUC) from day 0 to day 35. The AUC was determined
for each animal, and the mean ± SD of each group is shown. c Glucose tolerance tests (GTT) were performed in 10-hour fasted mice, 30 days after
T1D-MSC, C-MSC, or PBS intrasplenic administration. Glucose (1.5 mg/g) was intraperitoneally administered and blood glucose levels (mg/dl) were
determined 0, 15, 30, 60, and 180 minutes after administration. d AUC during GTT was determined for each animal and the means ± SD of each group
is shown. *P <0.05 (Control-PBS × C-MSCs); #P <0.05 (Control-PBS × T1D-MSCs). C-MSCs mesenchymal stromal cells from bone marrow of healthy
individuals, PBS phosphate-buffered saline, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients
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Fig. 5 T1D-MSC transplantation reduces insulitis and augments insulin production by pancreatic β cells in diabetic-treated mice. a Pancreata from
Control-PBS-treated, C-MSC-treated, and T1D-MSC-treated mice were collected 35 days after the treatments. Islet morphology was evaluated by H
& E staining and the in situ insulin content was detected by immunohistochemistry analysis. Representative H & E or insulin-stained islets from
the Control-PBS group (upper panel), C-MSC-treated group (middle panel), and T1D-MSC-treated group (lower panel) are shown. Original magnifica-
tion: 100×. b Blood samples were collected on day 35 and circulating-insulin levels were determined by ELISA. Bars represent mean ± SD. *P
<0.05 (Control-PBS × C-MSCs); #P <0.05 (Control-PBS × T1D-MSCs). C-MSCs mesenchymal stromal cells from bone marrow of healthy individuals, H
& E hematoxylin and eosin, PBS phosphate-buffered saline, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed
T1D patients
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and IL-17 were slightly decreased in the pancreas of C-
MSC-treated and T1D-MSC-treated responder mice com-
pared with the control group; however, these differences
were not significant (P >0.05; Fig. 7).
Discussion
MSCs have been considered to be a promising thera-
peutic approach for inflammatory diseases and AID, par-
ticularly because of their immunomodulatory properties.
The ability of MSCs to suppress the immune response
suggests a possible role of these cells to promote toler-
ance in AID, and supports their application in the treat-
ment of T1D. Satisfactory results of experimental studies
[20, 31–35] have encouraged the use of MSCs in several
T1D clinical trials worldwide [22]. However, researchers
and physicians still debate the best source of cells: allo-
geneic versus autologous MSCs. In an autologous trans-
plantation setting, the cells are not rejected by the host
immune system, additional immunosuppressive treat-
ment is dispensable, and transfer of donor-derived infec-
tions is unlikely. However, some pathological conditions
may affect MSC viability and functions, limiting their
use for autologous transplantation. In fact, MSCs iso-
lated from patients with AID presented defects in critical
functions. Impaired hematopoietic support, premature
loss of telomere length, and increased production of
TNFα have been reported in MSCs from patients with
RA [28, 36, 37]. Similarly, MSCs isolated from MS [29],
systemic lupus erythematosus (SLE) [38], and ITP [30]
patients present defective immunomodulatory proper-
ties. Whether phenotypical and functional properties of
MSCs derived from patients with T1D are normal or
somehow defective has not yet been established. Since
the autoimmune process and diabetic microenvironment
may change the biology of MSCs, it becomes important
to investigate whether these cells are suitable for autolo-
gous transplantation. Therefore, in this study we analyzed
MSCs isolated from the bone marrow of newly diagnosed
T1D patients and compared them with their healthy
counterparts.
T1D-MSCs exhibited typical morphology and similar
cell size compared with C-MSCs. Similarly, MSCs ob-
tained from MS [26, 39], RA [37], SS [27, 40, 41], and
Crohn’s disease [42] patients did not present morpho-
logical alterations compared with healthy counterparts.
On the other hand, MSCs isolated from patients with
ITP [30] and SLE [43] showed atypical morphology.
In our study, T1D-MSCs and C-MSCs presented typ-
ical expression of MSC surface markers and both cell
types were able to differentiate towards an adipocyte
lineage. Reports from the literature also describe that
MSCs from patients with MS [26, 39], SS [27, 40, 41],
SLE [43], or ITP [30] present similar immunophenotypic
profiles and in vitro differentiation capacity compared
with C-MSCs.
The immunomodulatory mechanisms of MSCs have
been explored extensively. A wide range of soluble fac-
tors has been involved in MSC immunomodulatory
function, including HGF, prostaglandin E2, TGF-β1,
IDO, nitric oxide (NO), IL-10, heme oxygenase-1, and
HLA-G [16, 44, 45]. MSCs develop their immunosup-
pressive functions after being exposed to the inflamma-
tory environment and this “licensing” step is provided
by molecules of acute phase inflammation, such as
IFNγ and TNFα, or TLR ligands [25]. In our microarray
analysis, the expression of immunomodulatory genes
(PDL1, NOS2, IL10, PTGES, TGFB1, PDL2, HLAG, and
TGS6) and licensing-related genes (IFNGR2, TNFR1,
IFNGR1, TNFR2, TLR4, and TLR3) was similar in T1D-
MSCs and C-MSCs. However, expression of the HGF
gene was downregulated in T1D-MSCs. In a previous
publication from our group [29], microarray analysis of
MSCs isolated from MS patients and healthy controls
revealed 618 differentially expressed genes, some of
Fig. 6 Treatment with T1D-MSCs does not affect the frequency of Treg cells in spleens and PLNs of diabetic mice. Frequency of regulatory CD4
+CD25+Foxp3+ T (Treg) cells was analyzed by flow cytometry in cell suspensions obtained from the a spleen and b PLN from T1D-MSC-treated,
C-MSC-treated, and PBS-treated mice. Cells were stained for surface markers CD4 and CD25, and subsequently for the transcription factor Foxp3.
Bars represent mean ± standard error of the mean. C-MSCs mesenchymal stromal cells from bone marrow of healthy individuals, PBS phosphate-
buffered saline, PLN pancreatic draining lymph nodes, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients
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them related to the impaired immunosuppressive cap-
acity of MSCs isolated from MS patients. Interestingly,
downregulation of HGF and TGFB1 genes and modula-
tion of HGF and FGF signaling pathways were reported.
In our present study, both patient and healthy donor
MSCs similarly inhibited allogeneic lymphocyte prolif-
eration in a dose-dependent manner. Likewise, MSCs
isolated from patients with juvenile idiopathic arthritis
[46], Crohn’s disease [42], SS [27], and SLE [43, 47]
showed preserved immunosuppressive capacity. Con-
versely, MSCs from MS [29] and ITP [30] patients ex-
hibited less in vitro T-cell antiproliferative activity
when compared with C-MSCs. Taking into account our
in silico and in vitro analyses, we suggest that T1D-
MSCs have preserved immunomodulatory function.
The therapeutic potential of T1D-MSCs to modulate
disease progression was tested in the STZ-induced dia-
betes model. MSCs were injected in mice 20 days after
diabetes induction, in the chronic phase of disease pro-
gression characterized by hyperglycemia, massive β-cell
destruction, and α-cell expansion with disruption of the
pancreatic islet architecture [48]. Different MSC delivery
routes were tested previously by our research group and
the intrasplenic route was the more effective to reverse
hyperglycemia in diabetic-treated mice [49]. The intrasple-
nic administration of MSCs effectively reversed diabetes
in 67 % of treated mice. Both T1D-MSC and C-MSC ap-
plications equivalently contributed to increase β-cell mass,
insulin production, and glucose tolerance. We can there-
fore infer that T1D-MSCs do not present functional ab-
normalities. Accordingly, Dong et al. showed that MSCs
isolated from diabetic rats decreased blood glucose levels
and prevented body weight loss when transplanted into
diabetic animals. The authors suggest that diabetes does
not influence MSC properties, supporting the use of au-
tologous MSCs in the treatment of T1D patients [50]. On
Fig. 7 Intrasplenic T1D-MSC administration modulates proinflammatory cytokines in the pancreatic tissue of STZ-induced diabetic mice. Pancreata
were obtained from Control and MSC-treated groups 35 days after treatment. The samples were weighed and homogenized in the presence of
proteases inhibitor. Levels of IL-2, IL-4, IL-17, IL-6, IFNγ, TNFα, and IL-10 were measured by cytokine beads array (CBA) method. The TGF-β level
was quantified by ELISA. Cytokine concentrations are represented by picograms of protein per gram of pancreatic tissue. Bars represent mean ± SD.
*P <0.05 (Control-PBS × C-MSCs); #P <0.05 (Control-PBS × T1D-MSCs). C-MSCs mesenchymal stromal cells from bone marrow of healthy individuals, IFN
interferon, IL interleukin, PBS phosphate-buffered saline, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients,
TGF-β transforming growth factor beta, TNFα tumor necrosis factor alpha
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the contrary, Fiorina et al. reported that MSCs isolated
from nonobese diabetic (NOD) mice were unable to delay
the onset of diabetes when administered to prediabetic
NOD mice and, furthermore, did not reverse hypergly-
cemia in mice with already established diabetes. The au-
thors then suggested that transplantation of MSCs derived
from nondiabetic donors, rather than autologous MSCs,
would be the best option for the treatment of T1D [21].
Studies have demonstrated the benefic role of MSCs
on in vivo and in vitro induction/proliferation of Treg
cells [51–53]. In our study, intrasplenic administration
of T1D-MSCs or C-MSCs did not affect the frequency
of CD4+CD25+Foxp3+ Treg cells in spleens and PLNs of
diabetic mice 35 days after MSC therapy. Fiorina et al.
[21] also did not observe significant modifications in the
frequency of Treg CD4+CD25+Foxp3+ cells in spleens
and PLN of NOD-treated mice 28 days after MSC ad-
ministration. However, opposing results were reported
by Madec et al. [20], who observed an increase in CD4
+Foxp3+ Treg cells 5 days after administration of MSCs
in diabetic NOD mice. Increased frequency of Treg cells
was also observed in STZ-induced diabetic mice 7 days
after MSC transplantation [31, 33]. Additionally, Jure-
wicz et al. reported increased levels of the regulatory
cytokine IL-10 in NOD mice 7 days after MSC injection.
However, this elevation was not detected on days 14 and
21 after cell therapy [32]. Our analyses were performed
35 days after MSC administration, which may represent
too long a period of time to detect alterations in Treg
cell frequency. We therefore believe that further experi-
ments should be performed earlier after cell transplant-
ation, to characterize immediate immune alterations
promoted by injected MSCs. Our results thus indicate
that the beneficial effects promoted by administration of
T1D-MSCs or C-MSCs are not related to late expansion
of Treg cells and that other mechanisms may be respon-
sible for the effective therapeutic response.
An inflammatory process (insulitis) was observed in
the pancreatic islets of PBS-treated mice but not in
those from MSC-treated mice. Additionally, levels of
IL-2 and IFNγ were decreased in the pancreatic hom-
ogenate of T1D-MSC-treated and C-MSC-treated mice
35 days after MSC administration. Moreover, a mar-
ginal but not substantial decrease in levels of IL-6,
TNFα, and IL-17 in the pancreatic tissue was observed
after MSC injections. Accordingly, allogeneic MSC ther-
apy decreased levels of pancreatic IFNγ in NOD-treated
mice [34]. Ezquer et al. [31] also observed that MSC ther-
apy induced a shift from a proinflammatory (IL-2, IFNγ,
and TNFα) to an anti-inflammatory (IL-13) cytokine pro-
file in diabetic mice. The decrease of proinflammatory
cytokine production observed in our work corroborates
these studies and may represent a possible mechanism by
which MSCs prevent pancreatic β-cell death and promote
reversion of hyperglycemia in the diabetic treated mice.
Moreover, the constraint of pancreatic inflammation en-
ables the preservation of residual and/or newly formed β
cells with regular insulin production.
MSCs from patients with chronic AID, such as MS [29]
and RA [28], showed abnormal cell characteristics and
functions compared with MSCs from healthy counter-
parts. In these chronic cases, some endogenous alterations
or previous immunomodulatory/immunosuppressive ther-
apies may have changed the bone marrow microenviron-
ment and affected MSC intrinsic pathways [10]. On the
other hand, we studied MSCs isolated from T1D patients
who were diagnosed in the previous 6 weeks, correspond-
ing to early stages after clinically overt disease. Recently,
Carlsson et al. treated recently diagnosed T1D patients
(<3 weeks before enrollment) with autologous MSCs.
Autologous MSC transplantation was safe and was able to
preserve or even increase C-peptide levels in T1D patients
[23]. Although limited by the small number of treated pa-
tients and short follow-up, the results from Carlsson et al.
[23] reinforce our data. We can suggest that MSCs from
recently diagnosed T1D individuals have their biological
and functional properties preserved, since there is no pro-
longed exposure to harmful inflammatory and metabolic
diabetic conditions. Further studies using MSCs from
chronic T1D patients will be necessary to evaluate the
influence of long-term diabetic environment on bone mar-
row MSC biological properties.
Conclusions
Our study provided for the first time a detailed
characterization of MSCs isolated from the bone mar-
row of newly diagnosed T1D patients. Compared with
their healthy counterparts, T1D-MSCs showed similar
morphology, immunophenotypic characteristics, adipocyte
differentiation potential, expression of immunomodula-
tory genes, and in vitro immunosuppressive capacity.
When administered to diabetic mice, T1D-MSCs and C-
MSCs similarly and successfully reversed hyperglycemia,
improved β-cell mass, increased insulin production, and
modulated pancreatic cytokine production. The present
results provide support for the use of autologous MSCs to
treat patients with recently diagnosed T1D.
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Additional file 1: Presents the supplementary methods. (DOCX 17 kb)
Additional file 2: Figure S1. Showing the experimental design.
Diabetes was induced in C57BL/6 male mice after daily intraperitoneal
injections of 40 mg/kg STZ for 5 consecutive days. Twenty days after
diabetes induction, mice were randomly divided into three experimental
groups: Control-PBS group (diabetic mice treated with PBS; n = 6), C-MSCs
group (diabetic mice treated with 1 × 106 MSCs isolated from healthy
individuals; n = 9), and T1D-MSCs group (diabetic mice treated with 1 × 106
MSCs isolated from newly diagnosed T1D patients; n = 9). Nonfasting
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glucose blood levels were frequently determined. Thirty-five days after PBS/
MSC administration, mice were sacrificed and different tissue samples were
collected and analyzed. (TIFF 381 kb)
Additional file 3: Figure S2. Showing the inflammatory process (insulitis)
into the pancreatic islets of PBS-treated diabetic mice. The pancreas of
diabetic mice was collected 35 days after PBS administration. Pancreatic
tissue section was analyzed by H & E staining. Insulitis is indicated by the
arrows. Original magnification: 100 × . (TIFF 8375 kb)
Additional file 4: Figure S3. Showing that C-MSC or T1D-MSC
transplantation does not change Ki-67 expression in pancreatic islet cells
of diabetic mice. Pancreata from the Control group, C-MSC-treated mice,
and T1D-MSC-treated mice were collected 35 days after the treatment.
Pancreatic tissue sections were analyzed by immunohistochemistry with
anti-Ki-67 antibody to evaluated proliferating pancreatic islet cells.
Representative images of pancreatic islets from Control-PBS group (left),
C-MSC-treated group (middle) and T1D-MSC-treated group (right) are
shown. Magnification: 200 × . (TIFF 790 kb)
Additional file 5: Figure S4. Showing the profile of serum
proinflammatory and anti-inflammatory cytokines does not change after
intrasplenic T1D-MSC administration. Blood samples were obtained from
Control and MSC-treated groups 35 days after treatment. Samples were
centrifuged and serum collected. Levels of IL-2, IL-4, IL-17, IL-6, IFNγ, TNFα,
and IL-10 were measured by cytokine beads array (CBA) method. Cytokine
concentrations are represented as picograms of protein per milliliter of
serum. Bars represent mean ± SD. (TIFF 57 kb)
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